Table of Contents Author Guidelines Submit a Manuscript
Journal of Oncology
Volume 2016 (2016), Article ID 9750785, 13 pages
http://dx.doi.org/10.1155/2016/9750785
Review Article

Curcumin and Resveratrol as Promising Natural Remedies with Nanomedicine Approach for the Effective Treatment of Triple Negative Breast Cancer

Translational Research Laboratory, Tata Memorial Centre, Advanced Centre for Treatment, Research and Education in Cancer (ACTREC), Navi Mumbai 410210, India

Received 30 December 2015; Revised 23 March 2016; Accepted 6 April 2016

Academic Editor: Rajendra Mehta

Copyright © 2016 Amol Shindikar et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. J. Ferlay, I. Soerjomataram, M. Ervik et al., Cancer Incidence and Mortality Worldwide, IARC Cancer Base no. 11, International Agency for Research on Cancer, Lyon, France, 2013, GLOBOCON, vol. 1, 2012, http://globocan.iarc.fr.
  2. Surveillance, Epidemiology, and End Results (SEER) Program, SEER∗Stat Database: Incidence—SEER 9 Regs Public-Use, Nov 2004 Sub (1973–2002), National Cancer Institute, DCCPS, Surveillance Research Program, Cancer Statistics Branch, April 2005, http://www.seer.cancer.gov/.
  3. J. O'Shaughnessy, “Extending survival with chemotherapy in metastatic breast cancer,” The Oncologist, vol. 10, no. 3, pp. 20–29, 2005. View at Publisher · View at Google Scholar · View at Scopus
  4. C. M. Perou, T. Sørile, M. B. Eisen et al., “Molecular portraits of human breast tumours,” Nature, vol. 406, no. 6797, pp. 747–752, 2000. View at Publisher · View at Google Scholar · View at Scopus
  5. T. Sørlie, C. M. Perou, R. Tibshirani et al., “Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications,” Proceedings of the National Academy of Sciences of the United States of America, vol. 98, no. 19, pp. 10869–10874, 2001. View at Publisher · View at Google Scholar · View at Scopus
  6. C. K. Anders and L. A. Carey, “Biology, metastatic patterns, and treatment of patients with triple-negative breast cancer,” Clinical Breast Cancer, vol. 9, supplement 2, pp. S73–S81, 2009. View at Publisher · View at Google Scholar · View at Scopus
  7. B. G. Haffty, Q. Yang, M. Reiss et al., “Locoregional relapse and distant metastasis in conservatively managed triple negative early-stage breast cancer,” Journal of Clinical Oncology, vol. 24, no. 36, pp. 5652–5657, 2006. View at Publisher · View at Google Scholar · View at Scopus
  8. L. Vona-Davis, D. P. Rose, H. Hazard et al., “Triple-negative breast cancer and obesity in a rural appalachian population,” Cancer Epidemiology Biomarkers and Prevention, vol. 17, no. 12, pp. 3319–3324, 2008. View at Publisher · View at Google Scholar · View at Scopus
  9. K. F. Trivers, M. J. Lund, P. L. Porter et al., “The epidemiology of triple-negative breast cancer, including race,” Cancer Causes and Control, vol. 20, no. 7, pp. 1071–1082, 2009. View at Publisher · View at Google Scholar · View at Scopus
  10. D. P. Atchley, C. T. Albarracin, A. Lopez et al., “Clinical and pathologic characteristics of patients with BRCA-positive and BRCA-negative breast cancer,” Journal of Clinical Oncology, vol. 26, no. 26, pp. 4282–4288, 2008. View at Publisher · View at Google Scholar · View at Scopus
  11. J. Fasano and F. Muggia, “Breast cancer arising in a BRCA-mutated background: therapeutic implications from an animal model and drug development,” Annals of Oncology, vol. 20, no. 4, pp. 609–614, 2009. View at Publisher · View at Google Scholar · View at Scopus
  12. S. R. Young, R. T. Pilarski, T. Donenberg et al., “The prevalence of BRCA1 mutations among young women with triple-negative breast cancer,” BMC Cancer, vol. 9, article 86, 2009. View at Publisher · View at Google Scholar · View at Scopus
  13. W. Park, A. R. Amin, Z. G. Chen, and D. M. Shin, “New perspectives of curcumin in cancer prevention,” Cancer Prevention Research, vol. 6, no. 5, pp. 387–400, 2013. View at Publisher · View at Google Scholar
  14. R. M. Srivastava, S. Singh, S. K. Dubey, K. Misra, and A. Khar, “Immunomodulatory and therapeutic activity of curcumin,” International Immunopharmacology, vol. 11, no. 3, pp. 331–341, 2011. View at Publisher · View at Google Scholar · View at Scopus
  15. D. Sinha, N. Sarkar, J. Biswas, and A. Bishayee, “Resveratrol for breast cancer prevention and therapy: preclinical evidence and molecular mechanisms,” Seminars in Cancer Biology, 2016. View at Publisher · View at Google Scholar
  16. B. J. Cridge, L. Larsen, and R. J. Rosengren, “Curcumin and its derivatives in breast cancer: current developments and potential for the treatment of drug-resistant cancers,” Oncology Discovery, vol. 1, article 6, 2013. View at Publisher · View at Google Scholar
  17. B. C. Litzenburger and P. H. Brown, “Advances in preventive therapy for estrogen-receptor-negative breast cancer,” Current Breast Cancer Reports, vol. 6, no. 2, pp. 96–109, 2014. View at Publisher · View at Google Scholar · View at Scopus
  18. L. G. Carter, J. A. D'Orazio, and K. J. Pearson, “Resveratrol and cancer: focus on in vivo evidence,” Endocrine-Related Cancer, vol. 21, no. 3, pp. R209–R225, 2014. View at Publisher · View at Google Scholar · View at Scopus
  19. M. Carocho and I. C. F. R. Ferreira, “The role of phenolic compounds in the fight against cancer—a review,” Anti-Cancer Agents in Medicinal Chemistry, vol. 13, no. 8, pp. 1236–1258, 2013. View at Publisher · View at Google Scholar · View at Scopus
  20. D. O. Kennedy and E. L. Wightman, “Herbal extracts and phytochemicals: plant secondary metabolites and the enhancement of human brain function,” Advances in Nutrition, vol. 2, no. 1, pp. 32–50, 2011. View at Publisher · View at Google Scholar · View at Scopus
  21. W. Kopeć, J. Telenius, and H. Khandelia, “Molecular dynamics simulations of the interactions of medicinal plant extracts and drugs with lipid bilayer membranes,” FEBS Journal, vol. 280, no. 12, pp. 2785–2805, 2013. View at Publisher · View at Google Scholar · View at Scopus
  22. L. G. Korkina, C. De Luca, V. A. Kostyuk, and S. Pastore, “Plant polyphenols and tumors: from mechanisms to therapies, prevention, and protection against toxicity of anti-cancer treatments,” Current Medicinal Chemistry, vol. 16, no. 30, pp. 3943–3965, 2009. View at Publisher · View at Google Scholar · View at Scopus
  23. N. Chainani-Wu, “Safety and anti-inflammatory activity of curcumin: a component of tumeric (Curcuma longa),” Journal of Alternative and Complementary Medicine, vol. 9, no. 1, pp. 161–168, 2003. View at Publisher · View at Google Scholar · View at Scopus
  24. P. Anand, S. G. Thomas, A. B. Kunnumakkara et al., “Biological activities of curcumin and its analogues (Congeners) made by man and Mother Nature,” Biochemical Pharmacology, vol. 76, no. 11, pp. 1590–1611, 2008. View at Publisher · View at Google Scholar · View at Scopus
  25. A. Deguchi, “Curcumin targets in inflammation and cancer,” Endocrine, Metabolic & Immune Disorders—Drug Targets, vol. 15, no. 2, supplement 9, pp. 88–96, 2015. View at Publisher · View at Google Scholar · View at Scopus
  26. M. K. Shanmugam, G. Rane, M. M. Kanchi et al., “The multifaceted role of curcumin in cancer prevention and treatment,” Molecules, vol. 20, no. 2, pp. 2728–2769, 2015. View at Publisher · View at Google Scholar
  27. P. Anand, C. Sundaram, S. Jhurani, A. B. Kunnumakkara, and B. B. Aggarwal, “Curcumin and cancer an ‘old-age’ disease with an ‘age-old’ solution,” Cancer Letters, vol. 267, no. 1, pp. 133–164, 2008. View at Google Scholar
  28. Z.-D. Lv, X.-P. Liu, W.-J. Zhao et al., “Curcumin induces apoptosis in breast cancer cells and inhibits tumor growth in vitro and in vivo,” International Journal of Clinical & Experimental Pathology, vol. 7, no. 6, pp. 2818–2824, 2014. View at Google Scholar · View at Scopus
  29. X.-D. Sun, X.-E. Liu, and D.-S. Huang, “Curcumin induces apoptosis of triple-negative breast cancer cells by inhibition of EGFR expression,” Molecular Medicine Reports, vol. 6, no. 6, pp. 1267–1270, 2012. View at Publisher · View at Google Scholar · View at Scopus
  30. P. Thulasiraman, D. J. McAndrews, and I. Q. Mohiudddin, “Curcumin restores sensitivity to retinoic acid in triple negative breast cancer cells,” BMC Cancer, vol. 14, article 724, 2014. View at Publisher · View at Google Scholar · View at Scopus
  31. M. Heger, R. F. van Golen, M. Broekgaarden, and M. C. Michel, “The molecular basis for the pharmacokinetics and pharmacodynamics of curcumin and its metabolites in relation to cancers,” Pharmacological Reviews, vol. 66, no. 1, pp. 222–307, 2013. View at Publisher · View at Google Scholar · View at Scopus
  32. P. Anand, A. B. Kunnumakkara, R. A. Newman, and B. B. Aggarwal, “Bioavailability of curcumin: problems and promises,” Molecular Pharmaceutics, vol. 4, no. 6, pp. 807–818, 2007. View at Publisher · View at Google Scholar · View at Scopus
  33. M. Bernsdorf, C. Ingvar, L. Jörgensen et al., “Effect of adding gefitinib to neoadjuvant chemotherapy in estrogen receptor negative early breast cancer in a randomized phase II trial,” Breast Cancer Research and Treatment, vol. 126, no. 2, pp. 463–470, 2011. View at Publisher · View at Google Scholar · View at Scopus
  34. B. J. Douglass and D. L. Clouatre, “Beyond yellow curry: assessing commercial curcumin absorption technologies,” Journal of the American College of Nutrition, vol. 34, no. 4, pp. 347–358, 2015. View at Publisher · View at Google Scholar · View at Scopus
  35. A. P. N. Majumdar, S. Banerjee, J. Nautiyal et al., “Curcumin synergizes with resveratrol to inhibit colon cancer,” Nutrition and Cancer, vol. 61, no. 4, pp. 544–553, 2009. View at Publisher · View at Google Scholar · View at Scopus
  36. S. Banerjee, C. Bueso-Ramos, and B. B. Aggarwal, “Suppression of 7,12-dimethylbenz(a)anthracene-induced mammary carcinogenesis in rats by resveratrol: role of nuclear factor-κB, cyclooxygenase 2, and matrix metalloprotease 9,” Cancer Research, vol. 62, no. 17, pp. 4945–4954, 2002. View at Google Scholar · View at Scopus
  37. T. Whitsett, M. Carpenter, and C. A. Lamartiniere, “Resveratrol, but not EGCG, in the diet suppresses DMBA-induced mammary cancer in rats,” Journal of Carcinogenesis, vol. 5, article 15, 2006. View at Publisher · View at Google Scholar · View at Scopus
  38. Y. Shi, S. Yang, S. Troup et al., “Resveratrol induces apoptosis in breast cancer cells by E2F1-mediated up-regulation of ASPP1,” Oncology Reports, vol. 25, no. 6, pp. 1713–1719, 2011. View at Publisher · View at Google Scholar · View at Scopus
  39. S. Bhattacharya, S. R. Darjatmoko, and A. S. Polans, “Resveratrol modulates the malignant properties of cutaneous melanoma through changes in the activation and attenuation of the antiapoptotic protooncogenic protein Akt/PKB,” Melanoma Research, vol. 21, no. 3, pp. 180–187, 2011. View at Publisher · View at Google Scholar · View at Scopus
  40. M. Ndiaye, C. Philippe, H. Mukhtar, and N. Ahmad, “The grape antioxidant resveratrol for skin disorders: promise, prospects, and challenges,” Archives of Biochemistry and Biophysics, vol. 508, no. 2, pp. 164–170, 2011. View at Publisher · View at Google Scholar · View at Scopus
  41. S.-J. Lee and M.-M. Kim, “Resveratrol with antioxidant activity inhibits matrix metalloproteinase via modulation of SIRT1 in human fibrosarcoma cells,” Life Sciences, vol. 88, no. 11-12, pp. 465–472, 2011. View at Publisher · View at Google Scholar · View at Scopus
  42. Z. Chen, K. Jin, L. Gao et al., “Anti-tumor effects of bakuchiol, an analogue of resveratrol, on human lung adenocarcinoma A549 cell line,” European Journal of Pharmacology, vol. 643, no. 2-3, pp. 170–179, 2010. View at Publisher · View at Google Scholar · View at Scopus
  43. L. Whyte, Y.-Y. Huang, K. Torres, and R. G. Mehta, “Molecular mechanisms of resveratrol action in lung cancer cells using dual protein and microarray analyses,” Cancer Research, vol. 67, no. 24, pp. 12007–12017, 2007. View at Publisher · View at Google Scholar · View at Scopus
  44. M. Sengottuvelan, P. Viswanathan, and N. Nalini, “Chemopreventive effect of trans-resveratrol—a phytoalexin against colonic aberrant crypt foci and cell proliferation in 1,2-dimethylhydrazine induced colon carcinogenesis,” Carcinogenesis, vol. 27, no. 5, pp. 1038–1046, 2006. View at Publisher · View at Google Scholar · View at Scopus
  45. S. H. Mitchell, W. Zhu, and C. Y. F. Young, “Resveratrol inhibits the expression and function of the androgen receptor in LNCaP prostate cancer cells,” Cancer Research, vol. 59, no. 23, pp. 5892–5895, 1999. View at Google Scholar · View at Scopus
  46. J. R. Stewart, M. C. Artime, and C. A. O'Brian, “Resveratrol: a candidate nutritional substance for prostate cancer prevention,” The Journal of Nutrition, vol. 133, no. 7, supplement, pp. 2440S–2443S, 2003. View at Google Scholar · View at Scopus
  47. K. B. Harikumar, A. B. Kunnumakkara, G. Sethi et al., “Resveratrol, a multitargeted agent, can enhance antitumor activity of gemcitabine in vitro and in orthotopic mouse model of human pancreatic cancer,” International Journal of Cancer, vol. 127, no. 2, pp. 257–268, 2010. View at Publisher · View at Google Scholar · View at Scopus
  48. N. Oi, C.-H. Jeong, J. Nadas et al., “Resveratrol, a red wine polyphenol, suppresses pancreatic cancer by inhibiting leukotriene A4 hydrolase,” Cancer Research, vol. 70, no. 23, pp. 9755–9764, 2010. View at Publisher · View at Google Scholar · View at Scopus
  49. A. Bishayee, T. Politis, and A. S. Darvesh, “Resveratrol in the chemoprevention and treatment of hepatocellular carcinoma,” Cancer Treatment Reviews, vol. 36, no. 1, pp. 43–53, 2010. View at Publisher · View at Google Scholar · View at Scopus
  50. T. Mbimba, P. Awale, D. Bhatia et al., “Alteration of hepatic pro-inflammatory cytokines is involved in the resveratrol-mediated chemoprevention of chemically-induced hepatocarcinogenesis,” Current Pharmaceutical Biotechnology, vol. 13, no. 1, supplement 6, pp. 229–234, 2012. View at Publisher · View at Google Scholar · View at Scopus
  51. P. R. van Ginkel, D. Sareen, L. Subramanian et al., “Resveratrol inhibits tumor growth of human neuroblastoma and mediates apoptosis by directly targeting mitochondria,” Clinical Cancer Research, vol. 13, pp. 5162–5169, 2007. View at Publisher · View at Google Scholar
  52. J. Dörrie, H. Gerauer, Y. Wachter, and S. J. Zunino, “Resveratrol induces extensive apoptosis by depolarizing mitochondrial membranes and activating caspase-9 in acute lymphoblastic leukemia cells,” Cancer Research, vol. 61, no. 12, pp. 4731–4739, 2001. View at Google Scholar · View at Scopus
  53. M.-F. Tsan, J. E. White, J. G. Maheshwari, and G. Chikkappa, “Anti-leukemia effect of resveratrol,” Leukemia & Lymphoma, vol. 43, no. 5, pp. 983–987, 2002. View at Publisher · View at Google Scholar · View at Scopus
  54. J. M. Smoliga and O. Blanchard, “Enhancing the delivery of resveratrol in humans: if low bioavailability is the problem, what is the solution?” Molecules, vol. 19, no. 11, pp. 17154–17172, 2014. View at Publisher · View at Google Scholar · View at Scopus
  55. R. Pangeni, J. K. Sahni, J. Ali, S. Sharma, and S. Baboota, “Resveratrol: review on therapeutic potential and recent advances in drug delivery,” Expert Opinion on Drug Delivery, vol. 11, no. 8, pp. 1285–1298, 2014. View at Publisher · View at Google Scholar · View at Scopus
  56. J. M. Smoliga, O. Vang, and J. A. Baur, “Challenges of translating basic research into therapeutics: resveratrol as an example,” Journals of Gerontology—Series A: Biological Sciences and Medical Sciences, vol. 67, no. 2, pp. 158–167, 2012. View at Publisher · View at Google Scholar · View at Scopus
  57. A. C. Santos, F. Veiga, and A. J. Ribeiro, “New delivery systems to improve the bioavailability of resveratrol,” Expert Opinion on Drug Delivery, vol. 8, no. 8, pp. 973–990, 2011. View at Publisher · View at Google Scholar · View at Scopus
  58. D. A. Benitez, E. Pozo-Guisado, A. Alvarez-Barrientos, P. M. Fernandez-Salguero, and E. A. Castellón, “Mechanisms involved in resveratrol-induced apoptosis and cell cycle arrest in prostate cancer-derived cell lines,” Journal of Andrology, vol. 28, no. 2, pp. 282–293, 2007. View at Publisher · View at Google Scholar · View at Scopus
  59. A. C. Faber and T. C. Chiles, “Resveratrol induces apoptosis in transformed follicular lymphoma OCI-LY8 cells: evidence for a novel mechanism involving inhibition of BCL6 signaling,” International Journal of Oncology, vol. 29, no. 6, pp. 1561–1566, 2006. View at Google Scholar · View at Scopus
  60. Y. Cao, Z.-D. Fu, F. Wang, H.-Y. Liu, and R. Han, “Anti-angiogenic activity of resveratrol, a natural compound from medicinal plants,” Journal of Asian Natural Products Research, vol. 7, no. 3, pp. 205–213, 2005. View at Publisher · View at Google Scholar · View at Scopus
  61. J. Leiro, J. A. Arranz, N. Fraiz, M. L. Sanmartín, E. Quezada, and F. Orallo, “Effect of cis-resveratrol on genes involved in nuclear factor kappa B signaling,” International Immunopharmacology, vol. 5, no. 2, pp. 393–406, 2005. View at Publisher · View at Google Scholar · View at Scopus
  62. Y. J. Chun, M. Y. Kim, and F. P. Guengerich, “Resveratrol is a selective human cytochrome P450 1A1 inhibitor,” Biochemical and Biophysical Research Communications, vol. 262, no. 1, pp. 20–24, 1999. View at Publisher · View at Google Scholar · View at Scopus
  63. A. M. Al-Abd, A. M. Mahmoud, G. A. El-Sherbiny et al., “Resveratrol enhances the cytotoxic profile of docetaxel and doxorubicin in solid tumour cell lines in vitro,” Cell Proliferation, vol. 44, no. 6, pp. 591–601, 2011. View at Publisher · View at Google Scholar · View at Scopus
  64. M. Russo, C. Spagnuolo, I. Tedesco, S. Bilotto, and G. L. Russo, “The flavonoid quercetin in disease prevention and therapy: facts and fancies,” Biochemical Pharmacology, vol. 83, no. 1, pp. 6–15, 2012. View at Publisher · View at Google Scholar · View at Scopus
  65. C. D. Lao, M. T. Ruffin IV, D. Normolle et al., “Dose escalation of a curcuminoid formulation,” BMC Complementary and Alternative Medicine, vol. 6, article 10, 2006. View at Publisher · View at Google Scholar · View at Scopus
  66. C. La Porte, N. Voduc, G. Zhang et al., “Steady-state pharmacokinetics and tolerability of trans-resveratrol 2000 mg twice daily with food, quercetin and alcohol (Ethanol) in healthy human subjects,” Clinical Pharmacokinetics, vol. 49, no. 7, pp. 449–454, 2010. View at Publisher · View at Google Scholar · View at Scopus
  67. M. D'Archivio, C. Filesi, R. D. Benedetto, R. Gargiulo, C. Giovannini, and R. Masella, “Polyphenols, dietary sources and bioavailability,” Annali dell'Istituto Superiore di Sanità, vol. 43, no. 4, pp. 348–361, 2007. View at Google Scholar
  68. A. J. Day and G. Williamson, “Biomarkers for exposure to dietary flavonoids: a review of the current evidence for identification of quercetin glycosides in plasma,” British Journal of Nutrition, vol. 86, supplement 1, pp. S105–S110, 2001. View at Publisher · View at Google Scholar · View at Scopus
  69. K. B. Pandey and S. I. Rizvi, “Plant polyphenols as dietary antioxidants in human health and disease,” Oxidative Medicine and Cellular Longevity, vol. 2, no. 5, pp. 270–278, 2009. View at Publisher · View at Google Scholar · View at Scopus
  70. K. D. R. Setchell, M. S. Faughnan, T. Avades et al., “Comparing the pharmacokinetics of daidzein and genistein with the use of 13C-labeled tracers in premenopausal women,” The American Journal of Clinical Nutrition, vol. 77, no. 2, pp. 411–419, 2003. View at Google Scholar · View at Scopus
  71. B. Wahlstrom and G. Blennow, “A study on the fate of curcumin in the rat,” Acta Pharmacologica et Toxicologica, vol. 43, no. 2, pp. 86–92, 1978. View at Google Scholar · View at Scopus
  72. G. Garcea, D. J. Jones, R. Singh et al., “Detection of curcumin and its metabolites in hepatic tissue andportal blood of patients following oral administration,” British Journal of Cancer, vol. 90, no. 5, pp. 1011–1015, 2004. View at Publisher · View at Google Scholar
  73. S. I. Hoehle, E. Pfeiffer, A. M. Sólyom, and M. Metzler, “Metabolism of curcuminoids in tissue slices and subcellular fractions from rat liver,” Journal of Agricultural and Food Chemistry, vol. 54, no. 3, pp. 756–764, 2006. View at Publisher · View at Google Scholar · View at Scopus
  74. G. M. Holder, J. L. Plummer, and A. J. Ryan, “The metabolism and excretion of curcumin (1,7-bis-(4-hydroxy-3-methoxyphenyl)-1,6-heptadiene-3,5-dione) in the rat,” Xenobiotica, vol. 8, no. 12, pp. 761–768, 1978. View at Publisher · View at Google Scholar · View at Scopus
  75. V. Ravindranath and N. Chandrasekhara, “Absorption and tissue distribution of curcumin in rats,” Toxicology, vol. 16, no. 3, pp. 259–265, 1980. View at Publisher · View at Google Scholar · View at Scopus
  76. M.-H. Pan, T.-M. Huang, and J.-K. Lin, “Biotransformation of curcumin through reduction and glucuronidation in mice,” Drug Metabolism & Disposition, vol. 27, no. 4, pp. 486–494, 1999. View at Google Scholar · View at Scopus
  77. S. K. Vareed, M. Kakarala, M. T. Ruffin et al., “Pharmacokinetics of curcumin conjugate metabolites in healthy human subjects,” Cancer Epidemiology Biomarkers & Prevention, vol. 17, no. 6, pp. 1411–1417, 2008. View at Publisher · View at Google Scholar · View at Scopus
  78. E. Wenzel and V. Somoza, “Metabolism and bioavailability of trans-resveratrol,” Molecular Nutrition & Food Research, vol. 49, no. 5, pp. 472–481, 2005. View at Publisher · View at Google Scholar · View at Scopus
  79. C. Yu, Y. G. Shin, A. Chow et al., “Human, rat, and mouse metabolism of resveratrol,” Pharmaceutical Research, vol. 19, no. 12, pp. 1907–1914, 2002. View at Publisher · View at Google Scholar · View at Scopus
  80. D. J. Boocock, G. E. S. Faust, K. R. Patel et al., “Phase I dose escalation pharmacokinetic study in healthy volunteers of resveratrol, a potential cancer chemopreventive agent,” Cancer Epidemiology Biomarkers & Prevention, vol. 16, no. 6, pp. 1246–1252, 2007. View at Publisher · View at Google Scholar · View at Scopus
  81. M. J. Hassett, A. J. O'Malley, J. R. Pakes, J. P. Newhouse, and C. C. Earle, “Frequency and cost of chemotherapy-related serious adverse effects in a population sample of women with breast cancer,” Journal of the National Cancer Institute, vol. 98, no. 16, pp. 1108–1117, 2006. View at Publisher · View at Google Scholar · View at Scopus
  82. J. Fang, H. Qin, H. Nakamura, K. Tsukigawa, T. Shin, and H. Maeda, “Carbon monoxide, generated by heme oxygenase-1, mediates the enhanced permeability and retention effect in solid tumors,” Cancer Science, vol. 103, no. 3, pp. 535–541, 2012. View at Publisher · View at Google Scholar · View at Scopus
  83. H. Hashizume, P. Baluk, S. Morikawa et al., “Openings between defective endothelial cells explain tumor vessel leakiness,” The American Journal of Pathology, vol. 156, no. 4, pp. 1363–1380, 2000. View at Publisher · View at Google Scholar · View at Scopus
  84. K. Iwai, H. Maeda, and T. Konno, “Use of oily contrast medium for selective drug targeting to tumor: enhanced therapeutic effect and X-ray image,” Cancer Research, vol. 44, no. 5, pp. 2115–2121, 1984. View at Google Scholar · View at Scopus
  85. T. Konno, H. Maeda, K. Iwai et al., “Selective targeting of anti-cancer drug and simultaneous image enhancement in solid tumors by arterially administered lipid contrast medium,” Cancer, vol. 54, no. 11, pp. 2367–2374, 1984. View at Google Scholar · View at Scopus
  86. A. J. Leu, D. A. Berk, A. Lymboussaki, K. Alitalo, and R. K. Jain, “Absence of functional lymphatics within a murine sarcoma: a molecular and functional evaluation,” Cancer Research, vol. 60, no. 16, pp. 4324–4327, 2000. View at Google Scholar · View at Scopus
  87. B.-H. Jeon, C. Jang, J. Han et al., “Profound but dysfunctional lymphangiogenesis via vascular endothelial growth factor ligands from CD11b+ macrophages in advanced ovarian cancer,” Cancer Research, vol. 68, no. 4, pp. 1100–1109, 2008. View at Publisher · View at Google Scholar · View at Scopus
  88. T. Safra, F. Muggia, S. Jeffers et al., “Pegylated liposomal doxorubicin (Doxil): reduced clinical cardiotoxicity in patients reaching or exceeding cumulative doses of 500 mg/m2,” Annals of Oncology, vol. 11, no. 8, pp. 1029–1033, 2000. View at Publisher · View at Google Scholar · View at Scopus
  89. S. Prasad, A. K. Tyagi, and B. B. Aggarwal, “Recent developments in delivery, bioavailability, absorption and metabolism of curcumin: the golden pigment from golden spice,” Cancer Research and Treatment, vol. 46, no. 1, pp. 2–18, 2014. View at Publisher · View at Google Scholar · View at Scopus
  90. V. Vetvicka, “Glucan-immunostimulant, adjuvant, potential drug,” World Journal of Clinical Oncology, vol. 2, no. 2, pp. 115–119, 2011. View at Publisher · View at Google Scholar
  91. S. Bisht, G. Feldmann, S. Soni et al., “Polymeric nanoparticle-encapsulated curcumin (‘nanocurcumin’): a novel strategy for human cancer therapy,” Journal of Nanobiotechnology, vol. 5, article 3, 2007. View at Publisher · View at Google Scholar · View at Scopus
  92. W. Tiyaboonchai, W. Tungpradit, and P. Plianbangchang, “Formulation and characterization of curcuminoids loaded solid lipid nanoparticles,” International Journal of Pharmaceutics, vol. 337, no. 1-2, pp. 299–306, 2007. View at Publisher · View at Google Scholar · View at Scopus
  93. L. Guo, Y. Peng, J. Yao, L. Sui, A. Gu, and J. Wang, “Anticancer activity and molecular mechanism of resveratrol-bovine serum albumin nanoparticles on subcutaneously implanted human primary ovarian carcinoma cells in nude mice,” Cancer Biotherapy and Radiopharmaceuticals, vol. 25, no. 4, pp. 471–477, 2010. View at Publisher · View at Google Scholar · View at Scopus
  94. J. Shao, X. Li, X. Lu et al., “Enhanced growth inhibition effect of resveratrol incorporated into biodegradable nanoparticles against glioma cells is mediated by the induction of intracellular reactive oxygen species levels,” Colloids and Surfaces B: Biointerfaces, vol. 72, no. 1, pp. 40–47, 2009. View at Publisher · View at Google Scholar · View at Scopus
  95. K. Teskač and J. Kristl, “The evidence for solid lipid nanoparticles mediated cell uptake of resveratrol,” International Journal of Pharmaceutics, vol. 390, no. 1, pp. 61–69, 2010. View at Publisher · View at Google Scholar · View at Scopus
  96. V. Sanna, I. A. Siddiqui, M. Sechi, and H. Mukhtar, “Resveratrol-loaded nanoparticles based on poly(epsiloncaprolactone) and poly(D,L-lactic-co-glycolic acid)-poly(ethylene glycol) blend for prostate cancer treatment,” Molecular Pharmaceutics, vol. 10, no. 10, pp. 3871–3881, 2013. View at Publisher · View at Google Scholar · View at Scopus
  97. S. S. Darandale and P. R. Vavia, “Cyclodextrin-based nanosponges of curcumin: formulation and physicochemical characterization,” Journal of Inclusion Phenomena and Macrocyclic Chemistry, vol. 75, no. 3-4, pp. 315–322, 2013. View at Publisher · View at Google Scholar · View at Scopus
  98. F. Trotta and R. Cavalli, “Characterization and applications of new hyper-cross-linked cyclodextrins,” Composite Interfaces, vol. 16, no. 1, pp. 39–48, 2009. View at Publisher · View at Google Scholar · View at Scopus
  99. F. Trotta, M. Zanetti, and R. Cavalli, “Cyclodextrin-based nanosponges as drug carriers,” Beilstein Journal of Organic Chemistry, vol. 8, pp. 2091–2099, 2012. View at Publisher · View at Google Scholar · View at Scopus
  100. E. K. Patel and R. J. Oswal, “Nanosponge and microsponges: a Novel Drug Delivery System,” International Journal of Research in Pharmacy and Chemistry, vol. 2, no. 2, pp. 2281–2781, 2012. View at Google Scholar
  101. J. Alongi, M. Poskovic, A. Frache, and F. Trotta, “Role of β-cyclodextrin nanosponges in polypropylene photooxidation,” Carbohydrate Polymers, vol. 86, no. 1, pp. 127–135, 2011. View at Publisher · View at Google Scholar · View at Scopus
  102. K. William, S. Benjamin, and H. Eva, “Synthesis and characterization of nanosponges for drug delivery and cancer treatment,” December 2011, http://www.vanderbilt.edu/vinse/docs/William-Kornahrens-Student-Poster.pdf.
  103. S. J. Torne, K. A. Ansari, P. R. Vavia, F. Trotta, and R. Cavalli, “Enhanced oral paclitaxel bioavailability after administration of paclitaxel-loaded nanosponges,” Drug Delivery, vol. 17, no. 6, pp. 419–425, 2010. View at Publisher · View at Google Scholar · View at Scopus
  104. K. A. Ansari, S. J. Torne, P. R. Vavia, F. Trotta, and R. Cavalli, “Paclitaxel loaded nanosponges: in-vitro characterization and cytotoxicity study on MCF-7 cell line culture,” Current Drug Delivery, vol. 8, no. 2, pp. 194–202, 2011. View at Publisher · View at Google Scholar · View at Scopus
  105. L. Li, F. S. Braiteh, and R. Kurzrock, “Liposome-encapsulated curcumin,” Cancer, vol. 104, no. 6, pp. 1322–1331, 2005. View at Publisher · View at Google Scholar · View at Scopus
  106. L. Li, F. S. Braiteh, and R. Kurzrock, “Liposome-encapsulated curcumin: in vitro and in vivo effects on proliferation, apoptosis, signaling, and angiogenesis,” Cancer, vol. 104, no. 6, pp. 1322–1331, 2005. View at Publisher · View at Google Scholar · View at Scopus
  107. X.-X. Wang, Y.-B. Li, H.-J. Yao et al., “The use of mitochondrial targeting resveratrol liposomes modified with a dequalinium polyethylene glycol-distearoylphosphatidyl ethanolamine conjugate to induce apoptosis in resistant lung cancer cells,” Biomaterials, vol. 32, no. 24, pp. 5673–5687, 2011. View at Publisher · View at Google Scholar · View at Scopus
  108. C. Caddeo, K. Teskač, C. Sinico, and J. Kristl, “Effect of resveratrol incorporated in liposomes on proliferation and UV-B protection of cells,” International Journal of Pharmaceutics, vol. 363, no. 1-2, pp. 183–191, 2008. View at Publisher · View at Google Scholar
  109. D. Suresh and K. Srinivasan, “Tissue distribution & elimination of capsaicin, piperine & curcumin following oral intake in rats,” Indian Journal of Medical Research, vol. 131, no. 5, pp. 682–691, 2010. View at Google Scholar · View at Scopus
  110. Z. Ma, A. Shayeganpour, D. R. Brocks, A. Lavasanifar, and J. Samuel, “High-performance liquid chromatography analysis of curcumin in rat plasma: application to pharmacokinetics of polymeric micellar formulation of curcumin,” Biomedical Chromatography, vol. 21, no. 5, pp. 546–552, 2007. View at Publisher · View at Google Scholar · View at Scopus
  111. S. Nunes, R. Madureira, D. Campos et al., “Solid lipid nanoparticles as oral delivery systems of phenolic compounds: overcoming pharmacokinetic limitations for nutraceutical applications,” Critical Reviews in Food Science and Nutrition, 2015. View at Publisher · View at Google Scholar
  112. N. K. Narayanan, D. Nargi, C. Randolph, and B. A. Narayanan, “Liposome encapsulation of curcumin and resveratrol in combination reduces prostate cancer incidence in PTEN knockout mice,” International Journal of Cancer, vol. 125, no. 1, pp. 1–8, 2009. View at Publisher · View at Google Scholar · View at Scopus
  113. F. Figueiró, A. Bernardi, R. L. Frozza et al., “Resveratrol-loaded lipid-core nanocapsules treatment reduces in vitro and in vivo glioma growth,” Journal of Biomedical Nanotechnology, vol. 9, no. 3, pp. 516–526, 2013. View at Publisher · View at Google Scholar · View at Scopus
  114. K. Cho, X. Wang, S. Nie, Z. Chen, and D. M. Shin, “Therapeutic nanoparticles for drug delivery in cancer,” Clinical Cancer Research, vol. 14, no. 5, pp. 1310–1316, 2008. View at Publisher · View at Google Scholar · View at Scopus
  115. S. K. Sahoo and V. Labhasetwar, “Enhanced antiproliferative activity of transferrin-conjugated paclitaxel-loaded nanoparticles is mediated via sustained intracellular drug retention,” Molecular Pharmaceutics, vol. 2, no. 5, pp. 373–383, 2005. View at Publisher · View at Google Scholar · View at Scopus
  116. L. Xu, K. F. Pirollo, W.-H. Tang, A. Rait, and E. H. Chang, “Transferrin-liposome-mediated systemic p53 gene therapy in combination with radiation results in regression of human head and neck cancer xenografts,” Human Gene Therapy, vol. 10, no. 18, pp. 2941–2952, 1999. View at Publisher · View at Google Scholar · View at Scopus
  117. Z. M. Qian, H. Li, H. Sun, and K. Ho, “Targeted drug delivery via the transferrin receptor-mediated endocytosis pathway,” Pharmacological Reviews, vol. 54, no. 4, pp. 561–587, 2002. View at Publisher · View at Google Scholar · View at Scopus
  118. M. Mollazade, K. Nejati-Koshki, A. Akbarzadeh et al., “PAMAM dendrimers augment inhibitory effects of curcumin on cancer cell proliferation: possible inhibition of telomerase,” Asian Pacific Journal of Cancer Prevention, vol. 14, no. 11, pp. 6925–6928, 2013. View at Publisher · View at Google Scholar · View at Scopus
  119. H. Tang, C. J. Murphy, B. Zhang et al., “Amphiphilic curcumin conjugate-forming nanoparticles as anticancer prodrug and drug carriers: in vitro and in vivo effects,” Nanomedicine, vol. 5, no. 6, pp. 855–865, 2010. View at Publisher · View at Google Scholar · View at Scopus
  120. D. J. McClements, Food Emulsions: Principles, Practice and Techniques, CRC Press, Boca Raton, Fla, USA, 2005.
  121. S. Schultz, G. Wagner, K. Urban, and J. Ulrich, “High-pressure homogenization as a process for emulsion formation,” Chemical Engineering and Technology, vol. 27, no. 4, pp. 361–368, 2004. View at Publisher · View at Google Scholar · View at Scopus
  122. C. J. H. Porter, C. W. Pouton, J. F. Cuine, and W. N. Charman, “Enhancing intestinal drug solubilisation using lipid-based delivery systems,” Advanced Drug Delivery Reviews, vol. 60, no. 6, pp. 673–691, 2008. View at Publisher · View at Google Scholar · View at Scopus
  123. F. Donsí, Y. Wang, J. I. Li, and Q. Huang, “Preparation of curcumin sub-micrometer dispersions by High-Pressure Homogenization,” Journal of Agricultural and Food Chemistry, vol. 58, no. 5, pp. 2848–2853, 2010. View at Publisher · View at Google Scholar · View at Scopus
  124. E. Wenzel and V. Somoza, “Metabolism and bioavailability of trans-resveratrol,” Molecular Nutrition and Food Research, vol. 49, no. 5, pp. 472–481, 2005. View at Publisher · View at Google Scholar · View at Scopus
  125. F. Donsì, M. Sessa, H. Mediouni, A. Mgaidi, and G. Ferrari, “Encapsulation of bioactive compounds in nanoemulsion- based delivery systems,” Procedia Food Science, vol. 1, pp. 1666–1671, 2011. View at Publisher · View at Google Scholar
  126. S. Mangalathillam, N. S. Rejinold, A. Nair, V.-K. Lakshmanan, S. V. Nair, and R. Jayakumar, “Curcumin loaded chitin nanogels for skin cancer treatment via the transdermal route,” Nanoscale, vol. 4, no. 1, pp. 239–250, 2012. View at Publisher · View at Google Scholar · View at Scopus
  127. X. Wei, T. H. Senanayake, G. Warren, and S. V. Vinogradov, “Hyaluronic acid-based nanogel-drug conjugates with enhanced anticancer activity designed for the targeting of CD44-positive and drug-resistant tumors,” Bioconjugate Chemistry, vol. 24, no. 4, pp. 658–668, 2013. View at Publisher · View at Google Scholar · View at Scopus
  128. Q. Du, B. Hu, H.-M. An et al., “Synergistic anticancer effects of curcumin and resveratrol in Hepa1-6 hepatocellular carcinoma cells,” Oncology Reports, vol. 29, no. 5, pp. 1851–1858, 2013. View at Publisher · View at Google Scholar · View at Scopus
  129. L. Masuelli, E. Di Stefano, M. Fantini et al., “Resveratrol potentiates the in vitro and in vivo anti-tumoral effects of curcumin in head and neck carcinomas,” Oncotarget, vol. 5, no. 21, pp. 10745–10762, 2014. View at Publisher · View at Google Scholar · View at Scopus
  130. P. Mohapatra, S. R. Satapathy, S. Siddharth, D. Das, A. Nayak, and C. N. Kundu, “Resveratrol and curcumin synergistically induces apoptosis in cigarette smoke condensate transformed breast epithelial cells through a p21Waf1/Cip1 mediated inhibition of Hh-Gli signaling,” International Journal of Biochemistry and Cell Biology, vol. 66, pp. 75–84, 2015. View at Publisher · View at Google Scholar · View at Scopus
  131. K. Coradini, F. O. Lima, C. M. Oliveira et al., “Co-encapsulation of resveratrol and curcumin in lipid-core nanocapsules improves their in vitro antioxidant effects,” European Journal of Pharmaceutics and Biopharmaceutics, vol. 88, no. 1, pp. 178–185, 2014. View at Publisher · View at Google Scholar · View at Scopus
  132. L. J. Carlson, B. Cote, A. W. Alani, and D. A. Rao, “Polymeric micellar co-delivery of resveratrol and curcumin to mitigate in vitro doxorubicin-induced cardiotoxicity,” Journal of Pharmaceutical Sciences, vol. 103, no. 8, pp. 2315–2322, 2014. View at Publisher · View at Google Scholar · View at Scopus
  133. K. C. Lund and T. Pantuso, “Combination effects of quercetin, resveratrol and curcumin on in vitro intestinal absorption,” Journal of Restorative Medicine, vol. 3, pp. 112–120, 2014. View at Google Scholar